Navigation Links
Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study
Date:6/16/2009

ROCKVILLE, Md., June 16 /PRNewswire-USNewswire/ -- According to a new report by HHS' Agency for Healthcare Research and Quality, there is insufficient evidence to conclude that genetic testing for two gene mutations in adults with a history of blood clots helps to prevent a condition known as deep-vein thrombosis or to improve other clinical outcomes.

The report, a summary of which will be published in the June 17 issue of JAMA, also failed to find any benefit from genetic testing of family members of patients who have at least one of the two mutations -- known as Factor V Leiden (FVL) and prothrombin G20210A -- as well as a history of deep-vein thrombosis.

As many as 600,000 Americans each year may have deep-vein thrombosis -- blood clots that form in the legs or pelvis. The condition occurs most commonly in people who are sedentary for a long period of time, such as when recovering from surgery or traveling long distances. The true number of people who develop a pulmonary embolism is unknown, but AHRQ data for hospital patients show that 258,000 individuals were diagnosed with the condition in 2006, and 20,000 died as a result.

"While genetic testing shows great promise to improve treatment and prevent disease, this report clearly shows that we need more research and evidence to achieve its full potential," said AHRQ Director Carolyn M. Clancy, M.D. "But people can help reduce their likelihood of developing a blood clot by talking with their doctor about precautions."

The evidence report was requested and supported by the Office of Public Health Genomics (OPHG) at HHS' Centers for Disease Control and Prevention. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, established by OPHG in 2005, will use this evidence report and other evidence to make recommendations on the validity and utility of genetic tests for FVL and prothrombin G20210A. This report, titled Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism, is the fifth evidence report requested for EGAPP.

The authors, who were led by Jodi Segal, M.D., of the AHRQ-supported Johns Hopkins Evidence-based Practice Center in Baltimore, failed to find any studies that directly addressed the effect of genetic testing on patient outcomes, but they found research indicating that keeping patients who have a genetic tendency to develop blood clots on blood-thinning drugs such as warfarin reduces the chance of a future clot. This benefit appears to be similar to that seen in patients who do not have the genetic tendency to develop blood clots but who have a history of clots.

The authors also reviewed the evidence for the accuracy of the testing methods used to identify the FVL and prothrombin G20210A mutations, which can signal continued risk of blood clots. The evidence shows that tests for identifying the mutations have excellent analytic validity and that nearly all laboratories report accurate results.

The authors called for randomized trials with sufficiently large sample sizes and long-term follow-up, as well as other research to determine whether changing provider practice based on genetic test results improves patient outcomes.

Once the embargo lifts on June 16 at 4:00 p.m. EDT, AHRQ's evidence report will be available at http://www.ahrq.gov/downloads/pub/evidence/pdf/factorvleiden/fvl.pdf. For more AHRQ information on deep-vein thrombosis, see Preventing Hospital-Acquired Venous Thromboembolism: A Guide for Effective Quality Improvement, and Your Guide to Preventing and Treating Blood Clots, available in both English and Spanish. Free, single copies of all AHRQ publications are available by calling the AHRQ Publications Clearinghouse at (800) 358-9295 or by sending an e-mail to AHRQPubs@ahrq.hhs.gov.

Use Twitter to get AHRQ news updates: www.twitter.com/ahrqnews.


'/>"/>
SOURCE Agency for Healthcare Research & Quality
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. ValueOptions(R) Supports New Hospital-Based Performance Measures to Help Patients Get the Best Treatment for Inpatient and Outpatient Services
2. Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed
3. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
4. University of Miami Team Confirms Value of Monitoring Cell-Mediated Immunity Pre- and Post-Transplant in Management of Kidney Transplant Recipients
5. Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions
6. BRAVE-3 Questions Value of Abciximab in PCI for Heart Attack
7. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
8. Industry Executives Finding Value in Shift of Scientific Publications
9. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
10. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
11. Replikins LLC Finds West Nile Virus Replikin Count Has Reached Its Highest Recorded Value
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... SAN FRANCISCO and ORLANDO, Fla. ... (Nasdaq: NKTR ) today announced that positive ... NKTR-214, in patients with renal cell carcinoma (RCC) were ... immuno-stimulatory therapy designed to expand specific cancer-fighting T cells ... tumor micro-environment and increase expression of PD-1 on these ...
(Date:2/18/2017)... , Feb. 17, 2017 Research and Markets has ... report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America , ... period 2015 through 2022. Also, a six-year historic analysis is provided for ...
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
Breaking Medicine Technology:
(Date:2/20/2017)... (PRWEB) , ... February 20, 2017 , ... Researchers at ... thyroid cancer, as well as a marker that may predict response to a particular ... many other types of cancer as well. The new findings were published in Proceedings ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies ... by for a visit this week at HIMSS 2017 Conference & Exhibition. The ... the globe. Sensogram will be featured in the conference’s Connected Health Experience section, ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's ... building. A topping out ceremony on Friday marked the halfway point of construction and ... open in Fall 2018, will serve as a center for innovation aimed at finding ...
(Date:2/19/2017)... ... 19, 2017 , ... The Citadel’s new Swain Department of Nursing , ... Amelia Joseph, Ph.D. Joseph was engaged by the college as a consultant to help ... 2016. After a nation-wide search, she was selected to head the department as nurse ...
(Date:2/19/2017)... ... February 19, 2017 , ... Orbita, Inc., a ... with Healthwise ® at HIMSS 2017 to showcase a breakthrough ... health education, technology and services, will demonstrate a voice-powered knowedge assistant based on ...
Breaking Medicine News(10 mins):